{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "be:CD8",
      "entity_text" : "CD8",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01892",
      "entity_text" : "PD-1 receptor",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Tumor cells express the PD-1 receptor ligand that inhibits the proliferation and survival of CD8 + cytotoxic cells.2 Nivolumab and another anti-PD-1 agent, pembrolizumab, have recently been registered by FDA as treatment for metastatic melanoma.",
  "reading_complete" : "2020-08-02T10:34:58Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T10:34:06Z",
  "trigger" : "inhibits",
  "evidence" : [ "PD-1 receptor ligand that inhibits the proliferation and survival of CD8" ],
  "pmc_id" : "6552946",
  "score" : 0
}